Medicus Amends LifeArc Deal, Lowers Teverelix Royalties, Revises Licensing Terms For GnRH Antagonist Teverelix

Medicus Pharma announced that its subsidiary, Antev Ltd., has amended its licensing agreement with UK-based medical research organisation LifeArc covering Teverelix, a long-acting next-generation GnRH antagonist in development. The revised deal lowers the royalty rate on global net sales from about 4% to 2% and clarifies royalty terms on a country-by-country basis, while leaving the scope of the license, intellectual property rights, and development responsibilities unchanged.

The original agreement grants Medicus exclusive worldwide rights to develop, manufacture and commercialise Teverelix, along with the ability to sublicense the asset broadly to support international partnerships. Medicus retains full operational control of the program and will continue to own any new improvements or enhancements developed through its work, helping expand the product’s intellectual property estate and long-term commercial potential.

“This amendment substantially improves the long-term economic profile of Teverelix while preserving the strength and integrity of the underlying license,” stated Dr. Raza Bokhari, Medicus Exec. Chairman & CEO, “we believe the reduced royalty burden enhances Teverelix’s attractiveness for future partnering, especially for late-stage development and commercialization.”

According to the company, the updated economic terms reflect scientific progress made by the Antev team and the strengthening of Teverelix’s global patent portfolio. The streamlined royalty structure is intended to better align the parties and support the efficient long-term advancement of the program.

LifeArc, which focuses on translating academic research into new medicines through industry partnerships, brings scientific expertise and long-term funding capacity to the collaboration. With more than £1 billion in assets under management, the organisation supports extended development programs and reinvests returns from successful partnerships into new medical research efforts.